crizanlizumab

01/01/2023 - "Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease."
01/01/2022 - "Crizanlizumab holds great promise in modulating the natural history of sickle cell disease and may have pleotropic effects. "
11/01/2021 - "Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study."
10/18/2023 - "Crizanlizumab in sickle cell disease."
06/01/2023 - "Crizanlizumab was approved by the United States Food and Drug Administration agency in 2019 for decreasing vaso-occlusive events (VOEs) in sickle cell disease (SCD). "

12/01/2021 - "(Crizanlizumab for Treating COVID-19 Vasculopathy [CRITICAL]; NCT04435184)."
12/01/2021 - "Crizanlizumab may induce thrombolysis in the setting of COVID-19. "
01/01/2023 - "Crizanlizumab, a P-selectin inhibitor, did not result in improvement in organ support-free days in patients hospitalized with COVID-19. "
01/01/2023 - "An international, adaptive, randomized controlled platform trial, funded by the National Heart, Lung, and Blood Institute, randomly assigned 422 patients hospitalized with COVID-19 with moderate or severe illness to receive either a single infusion of the P-selectin inhibitor crizanlizumab (at a dose of 5 mg/kg) plus standard of care or standard of care alone in an open-label 1:1 ratio. "
12/01/2021 - "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial."

12/01/2023 - "Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report."
01/01/2022 - "Additional benefits of crizanlizumab, in this case, were preventing new episodes of acute chest syndrome, quitting chronic narcotics use, and a remarkable improvement in quality of life and overall performance."

01/01/2022 - "Crizanlizumab reduced pain crises from 2.98 to 1.63 per year compared with placebo. "
07/01/2021 - "High-dose crizanlizumab led to a 45.3% lower median annual rate of sickle cell-related pain crises compared to placebo (P = 0.010), with no statistically significant difference for the low dose. "
02/28/2017 - "Crizanlizumab Prevents Sickle Cell Pain Crises."
01/01/2017 - "The primary end point was the annual rate of sickle cell-related pain crises with high-dose crizanlizumab versus placebo. "
01/01/2019 - "Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis."

06/01/2023 - "Fifteen patients received at least one dose of crizanlizumab 5 mg/kg of actual body weight during the study period. "
01/01/2017 - "In this double-blind, randomized, placebo-controlled, phase 2 trial, we assigned patients to receive low-dose crizanlizumab (2.5 mg per kilogram of body weight), high-dose crizanlizumab (5.0 mg per kilogram), or placebo, administered intravenously 14 times over a period of 52 weeks. "
01/01/2023 - "Crizanlizumab exhibits nonlinear pharmacokinetics in the wide dose range of 0.2-8 mg/kg body weight. "